RIFAXIMIN IS EFFICACIOUS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS PREVIOUSLY TREATED WITH OTHER IBS MEDICATIONS

被引：0
|
作者：
Rao, Satish S.
Schoenfeld, Philip S.
Heimanson, Zeev
Rezaie, Ali
Lacy, Brian E.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1329
引用
收藏
页码：S852 / S852
页数：1
相关论文
共 50 条
  • [21] Eluxadoline Demonstrates Efficacy for the Treatment of Irritable Bowel Syndrome (IBS) With Diarrhea (IBS-D) Among Multiple Clinically Relevant Patient Subgroups
    Lacy, Brian E.
    Chey, William
    Lembo, Anthony J.
    Dove, Leonard S.
    Covington, Paul S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S747 - S747
  • [22] RIFAXIMIN AND ELUXADOLINE UTILIZATION FOR IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN THE UNITED STATES AND BUDGET IMPACT ANALYSIS OF SWITCHING FROM ELUXADOLINE TO RIFAXIMIN
    Bloudek, L. M.
    Bozkaya, D.
    O'Hara, K.
    Kirby, S. K.
    Shah, S.
    VALUE IN HEALTH, 2018, 21 : S83 - S83
  • [23] INCLUSION OF A NOVEL IBS BLOOD PANEL FOR DIAGNOSING DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D): A UK PERSPECTIVE
    Soubieres, A.
    Pimentel, M.
    Purdy, C.
    Magar, R.
    VALUE IN HEALTH, 2015, 18 (07) : A350 - A350
  • [24] Irritable bowel syndrome: differentiating between IBS-D and IBS-O subtypes
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (04): : 350 - 350
  • [25] Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline (BL) pain severity
    Lembo, A.
    Heimanson, Z.
    Cash, B. D.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [26] Economic Burden of Irritable Bowel Syndrome (IBS) With Diarrhea (IBS-D): Retrospective Analyses of a US Commercially Insured Population
    Buono, Jessica
    Mathur, Kush
    Averitt, Amelia J.
    Andrae, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S922 - S923
  • [27] Psychosocial determinants of rifaximin adherence for the treatment of diarrhea-predominant irritable bowel syndrome (IBS)
    Sherwin, L.
    Krisanabud, P.
    Deroche, C.
    Matteson-Kome, M.
    Ruppar, T.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30
  • [28] Intestinal Spirochetosis in an Immunocompetent Patient Carrying a Diagnosis of Irritable Bowel Syndrome With Diarrhea (IBS-D)
    Kamionkowski, Sara
    Issak, Abdulfatah
    Jacobs, Jaclyn
    Zhang, Claire
    Waghray, Nisheet
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S949 - S949
  • [29] TREATMENT OF IBS-D CASES THROUGH RIFAXIMIN
    Shabir, Saba
    Gul, Qamar
    Zia, Jawariya
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (03): : 6517 - 6521
  • [30] Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
    Pimentel, Mark
    Chang, Lin
    Lembo, Anthony J.
    Wolf, Ray A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S761 - S761
12345